Literature DB >> 30120950

Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis.

David Bédard Méthot1, Évelyne Leblanc1, Yves Lacasse2.   

Abstract

BACKGROUND: The relationship between gastroesophageal reflux disease (GERD) and idiopathic pulmonary fibrosis (IPF) is controversial. Current guidelines recommend that clinicians use regular antacid treatment, while two recent meta-analyses of antacid therapy in IPF were inconclusive. The objective of this study was to examine the evidence regarding the association between GERD and IPF through a systematic review and a meta-analysis, with special reference to the methodologic quality of the observational studies.
METHODS: The MEDLINE, EMBASE, Ovid, and Web of Science (1966-May 2018) databases were searched for original articles published in any language, and we then systematically reviewed the bibliographies of the retrieved articles. Observational studies (cohort and case-control studies) were selected if they allowed the calculation of a measure of association relating GERD to IPF.
RESULTS: Eighteen case-control studies including 3,206 patients with IPF and 9,368 control subjects met the inclusion criteria of the meta-analysis. The meta-analysis indicated that GERD is associated with IPF (OR, 2.94 [95% CI, 1.95-4.42]; P homogeneity < .0001). Overall, the results remained consistent whatever the data source (clinical studies vs databases) or the type of control subject (healthy volunteers, patients with respiratory diseases other than interstitial lung disease, or patients with non-IPF interstitial lung disease). In a meta-regression, after controlling for smoking, GERD and IPF were not related.
CONCLUSIONS: GERD and IPF may be related, but this association is most likely confounded, especially by smoking. Our confidence in the estimate of association is low because it is exclusively from case-control studies. TRIAL REGISTRY: PROSPERO; No.: CRD42016053728; URL: http://www.crd.york.ac.uk/PROSPERO.
Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  gastroesophageal reflux; idiopathic pulmonary fibrosis; meta-analysis; systematic review

Mesh:

Year:  2018        PMID: 30120950     DOI: 10.1016/j.chest.2018.07.038

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA.

Authors:  Ayodeji Adegunsoye; Julie M Neborak; Daisy Zhu; Benjamin Cantrill; Nicole Garcia; Justin M Oldham; Imre Noth; Rekha Vij; Tomasz J Kuzniar; Shashi K Bellam; Mary E Strek; Babak Mokhlesi
Journal:  Chest       Date:  2020-05-22       Impact factor: 9.410

Review 2.  Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).

Authors:  Shigeki Saito; Ala Alkhatib; Jay K Kolls; Yasuhiro Kondoh; Joseph A Lasky
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.

Authors:  Sangmee Sharon Bae; Lila Pourzand; Grace Hyun Kim; Bianca E Villegas; Andrea Oh; Daniel E Furst; Jonathan Goldin; Donald P Tashkin
Journal:  J Scleroderma Relat Disord       Date:  2021-10-23

4.  Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.

Authors:  Eleanor Valenzi; Haopu Yang; John C Sembrat; Libing Yang; Spencer Winters; Rachel Nettles; Daniel J Kass; Shulin Qin; Xiaohong Wang; Michael M Myerburg; Barbara Methé; Adam Fitch; Jonathan K Alder; Panayiotis V Benos; Bryan J McVerry; Mauricio Rojas; Alison Morris; Georgios D Kitsios
Journal:  Thorax       Date:  2020-12-02       Impact factor: 9.139

5.  Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study.

Authors:  Misbah Baqir; Amit Vasirreddy; Ann N Vu; Teng Moua; Alanna M Chamberlain; Ryan D Frank; Jay H Ryu
Journal:  Respir Med       Date:  2021-01-22       Impact factor: 4.582

Review 6.  Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Authors:  Paola Faverio; Marialuisa Bocchino; Antonella Caminati; Alessia Fumagalli; Monica Gasbarra; Paola Iovino; Alessandra Petruzzi; Luca Scalfi; Alfredo Sebastiani; Anna Agnese Stanziola; Alessandro Sanduzzi
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

7.  Idiopathic pulmonary fibrosis and GERD: links and risks.

Authors:  Matteo Ghisa; Carla Marinelli; Vincenzo Savarino; Edoardo Savarino
Journal:  Ther Clin Risk Manag       Date:  2019-09-05       Impact factor: 2.423

8.  Assessment of the lung microbiota in dogs: influence of the type of breed, living conditions and canine idiopathic pulmonary fibrosis.

Authors:  Aline Fastrès; Elodie Roels; Emilie Vangrinsven; Bernard Taminiau; Hiba Jabri; Géraldine Bolen; Anne-Christine Merveille; Alexandru-Cosmin Tutunaru; Evelyne Moyse; Georges Daube; Cécile Clercx
Journal:  BMC Microbiol       Date:  2020-04-10       Impact factor: 3.605

9.  Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.

Authors:  Helen E Jo; Tamera J Corte; Ian Glaspole; Christopher Grainge; Peter M A Hopkins; Yuben Moodley; Paul N Reynolds; Sally Chapman; E Haydn Walters; Christopher Zappala; Heather Allan; Gregory J Keir; Wendy A Cooper; Annabelle M Mahar; Samantha Ellis; Sacha Macansh; Nicole S Goh
Journal:  BMC Pulm Med       Date:  2019-05-03       Impact factor: 3.317

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.